Welcome to our dedicated page for Alpha Cognition SEC filings (Ticker: ACOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alpha Cognition Inc. (NASDAQ: ACOG) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures. Alpha Cognition is an emerging growth, commercial-stage biopharmaceutical company focused on Alzheimer’s disease and other neurodegenerative conditions, and its filings offer detailed insight into how it finances, governs, and reports on its ZUNVEYL and ALPHA-1062 programs.
Through this page, users can review Current Reports on Form 8-K that document material events such as public offerings of common shares and pre-funded warrants, at-the-market offering agreements, changes in the independent registered public accounting firm, and adoption of equity incentive plans. For example, recent 8-Ks describe an underwriting agreement for a public offering intended to support ZUNVEYL commercialization, an ATM agreement with a sales agent for up to a specified aggregate amount of common shares, and the transition from a Canada-based auditor to a U.S.-licensed firm following relocation of principal executive offices to Texas.
Investors can also use this page to monitor corporate governance and compensation matters, including shareholder votes on the number of directors, director elections, ratification of auditors, and approval of stock incentive plans, as reported in meeting-related filings. These documents help clarify how Alpha Cognition structures its board, aligns management incentives, and complies with exchange and securities regulations.
Stock Titan enhances these filings with AI-powered summaries that highlight key terms, financial implications, and governance changes, reducing the time needed to interpret lengthy documents. Real-time integration with the SEC’s EDGAR system means new ACOG filings appear promptly, while dedicated sections for material agreements and capital markets activity make it easier to follow offerings, ATM usage, and other financing tools. For users interested in deeper due diligence on Alpha Cognition’s Alzheimer’s-focused business, this page serves as a structured entry point into the company’s official regulatory record.
Alpha Cognition Inc. appointed Bethany Sensenig to its board of directors effective April 15, 2026. She brings senior finance and operations experience from roles at Radius Health, 9 Meters Biopharma, Minovia Therapeutics, and a 13-year career at Biogen with P&L responsibility over about $1 billion in annual revenue across 30 countries.
As a non-employee director, she will be compensated under the company’s standard policy and received an initial equity grant of 5,489 restricted stock units and 6,991 stock options, with an exercise price of $6.65 per share. Both the RSUs and options vest one year after the grant date. The company states there are no arrangements, family relationships, or related-party transactions linked to her appointment.
Alpha Cognition Inc. director Bethany Sensenig reported equity awards consisting of stock options and restricted stock units as compensation. She received 6,991 Common Share Options at an exercise price of $6.65 per share, expiring on April 16, 2036, which will vest one year from the grant date. She also received 5,489 Common Shares in the form of restricted stock units that vest one year from the grant date. After these awards, her reported holdings are 6,991 options and 5,489 common shares held directly, and there were no open-market purchases or sales in this filing.
Alpha Cognition Inc. director Bethany Sensenig filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The excerpt shows no reported transactions, no derivative positions, and no listed holdings, indicating this filing is purely administrative disclosure at this time.
Alpha Cognition Inc. entered into a settlement agreement with Galantos Pharma GmbH to eliminate future contingent payment obligations tied to the Memogain asset and technology agreements. The company will make a one-time payment of EUR 5,214,220 to fully satisfy remaining royalty and milestone-related obligations under the Original Agreement.
In exchange for this lump-sum payment, Galantos will waive and release all related claims against Alpha Cognition and its affiliates. The settlement amount is described as representing an approximate 40% discount to the estimated market value of the remaining obligations, based on management’s assessment of projected future payments and comparable market benchmarks.
Alpha Cognition Inc. is a biopharmaceutical company focused on neurodegenerative diseases, particularly Alzheimer’s. It has shifted from pure R&D to commercialization with the U.S. launch of ZUNVEYL, an oral acetylcholinesterase inhibitor for mild-to-moderate Alzheimer’s disease, on March 19, 2025.
The company is targeting the long-term care market, where acetylcholinesterase inhibitors account for a large share of more than 11 million annual U.S. prescriptions. ZUNVEYL’s wholesale acquisition cost is set at $820 per month, and Alpha Cognition is negotiating coverage with major pharmacy benefit managers.
Beyond ZUNVEYL, the pipeline includes a fixed-dose combination of ALPHA‑1062 and memantine for moderate-to-severe Alzheimer’s, a sublingual ALPHA‑1062 formulation for patients with swallowing difficulties, and programs in mild traumatic brain injury. A broad patent estate provides protection into the 2040s across multiple jurisdictions and formulations.
Alpha Cognition Inc. reported insider activity by investment manager Opaleye Management Inc., tied to positions held by its affiliated vehicles. On March 27, Opaleye, L.P. executed an open-market purchase of 10,000 common shares at an average price of $5.0792 per share. On March 30, the fund bought an additional 1,850 shares at $4.9873 per share. Following these trades, Opaleye, L.P. held 2,471,850 Alpha Cognition shares indirectly managed by Opaleye Management, and a separately managed account overseen by Opaleye held 90,000 shares. Opaleye Management states it may be deemed a beneficial owner through its roles but disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. set the date for its 2026 Annual General Meeting of Shareholders. The meeting will be held on June 16, 2026 in Texas. Shareholders of record on April 24, 2026 will be entitled to receive notice of, and vote at, the meeting.
The same April 24, 2026 date applies for voting and beneficial ownership determination. The company will use notice-and-access for both registered and beneficial holders, meaning proxy-related materials will be provided electronically, with no issuer-paid delivery to objecting beneficial owners.
Opaleye Management Inc., a 10% owner of Alpha Cognition Inc. (ACOG), reported a series of open-market share purchases in late March 2026. An affiliated fund, Opaleye, L.P., bought 4,182 common shares at $5.59 on March 24, 8,581 shares at a weighted average $5.4281 on March 25, and 7,319 shares at a weighted average $5.2842 on March 26.
Following these transactions, the fund held 2,460,000 Alpha Cognition common shares indirectly through Opaleye, L.P., and a separately managed account held an additional 90,000 shares. The filing notes these holdings are reported indirectly through Opaleye Management Inc., which disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. reported its fourth quarter and full-year 2025 results, highlighting early commercial traction for Alzheimer’s drug ZUNVEYL. Full-year 2025 revenue was $10.2 million, including $6.8 million in net product sales and $3.4 million in licensing revenue. Fourth-quarter 2025 ZUNVEYL net product revenue reached $2.5 million.
Bottles dispensed in the fourth quarter rose 62% sequentially to 4,941, with December the strongest month since launch. Year-end 2025 cash and cash equivalents were $66.0 million, up from $48.5 million a year earlier, supporting the company’s goal of reaching operational profitability in 2027. The company reported a 2025 net loss of $20.7 million, compared with $14.8 million in 2024, as selling, general and administrative expenses increased to $29.1 million to support commercialization.
Alpha Cognition Inc. reported insider activity by Opaleye-managed entities. Opaleye, L.P. purchased 2,481 common shares on March 18, 2026 at a weighted average price of $5.749 and 2,094 shares on March 19, 2026 at a weighted average price of $5.707 in open-market transactions.
After these buys, Opaleye, L.P. reported holding 2,439,918 Alpha Cognition shares, and a separately managed account overseen by Opaleye reported 90,000 shares. Opaleye Management Inc. may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.